BillionToOne Stock
BillionToOne, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Oguzhan Atay
- Employees
- 713
- Market cap
- $4.6 B
- IPO
- 06/11/2025
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby…
BillionToOne stock: price history
1D
-4.5%
1W
+0.0%
1M
-5.3%
6M
+23.5%
YTD
+19.9%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~118% stronger price swings than usual
BillionToOne stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 03/09/2026.
Business model & megatrends
Not calculated yet.
1 more assignment (Enabler/Second row) Pro-only.
BillionToOne is a specialized molecular diagnostics company that leverages a technological platform for precise quantification of biological data at the DNA level. Its product portfolio encompasses prenatal screening procedures as well as tests for cancer detection and monitoring through mutation analysis and methylation examination. By enabling the exact measurement of individual DNA molecules, the company facilitates more precise disease diagnostics and monitoring of disease progression.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about BillionToOne
Analyst assessment of BillionToOne
PRICE TARGET LOW
US$120.00
CONSENSUS
US$126.00
MEDIAN
US$128.00
PRICE TARGET HIGH
US$130.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 01/10/2026
BillionToOne stock metrics
P/E
142.18
P/B
8.48
EV/EBITDA
84.09
RETURN ON EQUITY
1.5%
NET MARGIN
7.4%
DEBT/EQUITY
0.27
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
11.9%
FLOAT SHARES
5,602,521
AVG. DAILY VOLUME (30D)
623,055
Insider transactions (SEC)
Atay Oguzhan
Atay Oguzhan
Atay Oguzhan
Atay Oguzhan
Atay Oguzhan
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.5%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about BillionToOne stock
What does BillionToOne do?
BillionToOne, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Oguzhan Atay, the company employs around 713 people.
The IPO was on 06/11/2025; the stock trades on NASDAQ under the ticker BLLN.
What do analysts say about BillionToOne stock?
4 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$126.00, ranging from US$120.00 to US$130.00, with a median of US$128.00.
This is an external assessment, not a statement by Market Jury.
When does BillionToOne report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 118% stronger than usual.
Does BillionToOne pay a dividend?
No, BillionToOne currently does not pay a dividend.
Which stocks are comparable to BillionToOne?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get BillionToOne stock analyzed?
Clicking "Analyze stock" lets five strategies assess BillionToOne against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.